



Mast cells in human choroid and their role in age-related macular degeneration (AMD)

Domenico Ribatti¹ · Rosanna Dammacco¹

Received: 25 March 2024 / Accepted: 28 April 2024 / Published online: 10 May 2024
© The Author(s) 2024

Abstract

The role of mast cells in physiologic and pathological processes extends far beyond the allergy processes: they are involved in wound healing, chronic inflammation, and tumor growth. This short article emphasizes the role played by mast cells in age-related macular degeneration (AMD). Mast cells can induce angiogenesis and are present around Bruch's membrane during the early and late stages of choroidal neovascularization in AMD. Proteolytic enzymes released by mast cells lead to thinning of the choroid in AMD as well as degradation of vascular basement membranes and Bruch's membrane, which in turn could result in retinal pigment epithelial death and choriocapillaris degeneration in geographical atrophy and exudative AMD.

Keywords Age-related macular degeneration · Angiogenesis · Inflammation · Mast cells

Introduction

Mast cells, first identified and described by Paul Ehrlich in his doctoral thesis in 1878 [3], originate from progenitor cells in the bone marrow, move through the circulation, and become mature after homing to different organs under the influence of the local microenvironment [7, 21]. Mast cells preferentially reside near surfaces exposed to environmental triggers, such as skin, airways, and gastrointestinal and urogenital tracts [22].

Mast cells have multiple roles extending beyond their classical role in IgE-mediated allergic reactions. When mast cells are activated, they degranulate releasing a wide range of already stored mediators, including histamine, serotonin, tumor necrosis factor alpha (TNF- α), proteoglycans and various proteases, and/or secrete newly synthesized lipid derivatives, cytokines, and chemokines. In this context, mast cells are involved in the regulation of the functions of many organs and tissues.

Although these cells secrete many pro-inflammatory agents, they also release many anti-inflammatory agents. In this context, mast cells can change from protective immune cells to potent pro-inflammatory cells which influence the

progression of many pathological conditions, including inflammatory diseases, autoimmune diseases, and tumors.

Inflammation in age-related macular degeneration

Age-related macular degeneration (AMD) is a multifactorial disease, including genetic predisposition, oxidative stress, neovascularization, inflammatory responses, and remodeling processes of the retinal extracellular matrix, characterized by progressive degeneration of the photoreceptor/retinal pigment epithelium/choriocapillaris complex primarily in the macular region of the eye, resulting in irreversible central vision loss.

There are mainly two types of AMD: dry (also named non-neovascular, non-exudative, or atrophic) AMD and wet (also named neovascular or exudative) AMD (nAMD) [17]. Dry AMD is characterized by the increase of extracellular deposits called drusen, along with advanced-stage geographical atrophy which is characterized by decreasing retinal pigment epithelium cells, photoreceptors, and choroidal capillaries. Wet AMD is characterized by choroidal neovascularization, leading to severe and fast vision impairment, accompanied by hard exudate, leaking fluid or retinal hemorrhage, retinal pigment epithelium detachment, or fibrosis around neovascular tufts [17].

Literature evidence suggests that inflammation plays an important role in its pathogenesis. Leukocytes are closely correlated with AMD pathogenesis, and both innate and

✉ Domenico Ribatti
domenico.ribatti@uniba.it

¹ Department of Translational Biomedicine and Neuroscience, University of Bari Medical School, Bari, Italy

adaptive immune cells play key roles in AMD [2]. Innate immune cells (macrophages, dendritic cells, and neutrophils) can stimulate adaptive immune cells (B cells and T cells) and participate in choroid neovascularization pathogenesis [1]. The levels of pro-inflammatory factors such as interleukin (IL)-6, IL-8, monocyte chemoattractant protein-1 (MCP-1), and vascular endothelial growth factor (VEGF) are elevated in the intraocular fluid of patients with dry and wet AMD. Cytokines, including VEGF, IL-1 β , IL-6, IL-8, IL-10, IL-17, transforming growth factor beta (TGF- β), and TNF- α , have angiogenic properties, whereas IL-4, IL-12, and interferon beta (IFN- β) inhibit angiogenesis.

Mast cells in the eye

In the eye, mast cells are present in the uveal tract, iris, ciliary body, and choroid of different animal species [13]. In humans, mast cells are abundant in the anterior and posterior uvea but are absent in the retina [8, 11]. Within the choroid, mast cells have a characteristic periarteriolar distribution [13], primarily along the long posterior ciliary arteries (LPCA) and their branches [13].

In the 1960s, Enerbäck described two morphologically distinct subpopulations of rodent mast cells, based on their specific staining characteristics and preferential tissue homing, i.e., connective tissue mast cells (CTMCs) present in the connective tissues, and mucosal mast cells (MMC) located on the mucosae of the respiratory and gastrointestinal tracts. CTMCs could be distinguished from MMCs by red staining with safranin due to the presence of large amounts of heparin in their secretory granules. After appropriate fixation and sequential staining with Alcian blue and safranin, MMCs stain blue, being thus differentiated from CTMCs which stain with safranin and are red. Differential affinity for Alcian blue can be visualized with sequential staining, consisting of Alcian blue followed by safranin [20]. Histochemical studies have revealed rat choroidal mast cells are of the connective tissue phenotype, containing mixed Alcian blue/safranin-positive granules. Transmission electron microscopy confirms these findings by revealing rat choroidal mast cell granules to be of uniform diameter [13].

In humans, mast cells may be classified on the presence in their granules of high levels of tryptase but little or no chymase (MCT) in intestinal and pulmonary mucosa predominantly found at mucosal sites, or mast cells containing chymase, and little or no tryptase (MCC), and finally, mast cells containing tryptase, chymase, and carboxypeptidase (MCTC) predominantly found in the skin, lymph nodes, and lung and gut submucosa [6]. May [11] showed that most of the mast cells in the normal human choroid are of the MCTC variety, whereas McLeod et al. [15] found that MCT was the predominant variety in the choroid in aged

eyes with and without AMD. May [11] identified chymase- and tryptase-positive mast cells in the human uvea and studied their association with different types of resident uveal cells. Most of the choroidal mast cells contain both chymase and tryptase, in agreement with *in vitro* studies of choroidal cell suspensions [16]. In contrast, mast cells of ciliary and sphincter pupillae muscle express a specific, tryptase-positive, chymase-negative protease profile [11]. The human iris contains only a few mast cells. In rodents, the number of iris mast cells is even lower than in primates and humans [13]. On the other hand, in the human choroid, many mast cells are in the inner part toward the capillary layer. This difference in mast cell distribution coincides with characteristic structures of the vascular walls in both tissues. The vessels of the iris have a thick, perivascular sheath forming a barrier for larger molecules such as proteins. In contrast, the choriocapillaris is highly fenestrated, and antigenic substances can easily pass into the choroidal stroma. In this respect, the high number of mast cells in the inner choroid adjacent to the choriocapillaris might be necessary for an appropriate antigenic reaction.

Mast cells in AMD

Increased numbers of mast cells have previously been reported in the choroid of individuals with AMD [1]. Mast cells can induce angiogenesis and are present around Bruch's membrane during the early and late stages of choroidal neovascularization in AMD [18]. Proteolytic enzymes released by mast cells lead to thinning of the choroid in AMD as well as degradation of vascular basement membranes and Bruch's membrane, which in turn could result in retinal pigment epithelial death and choriocapillaris degeneration in geographical atrophy and exudative AMD [14]. Finally, mast cell releases angiogenic factors and proteases that promote vascularization, including VEGFA, fibroblast growth factor-2 (FGF-2), IL-8, nerve growth factor (NGF), TGF β , TNF α , heparin, histamine, tryptase, chymase, MMP-2, and MMP-9 [19] that may contribute to neovascularization occurring in AMD.

Therapeutic approach

Intravitreal injections of anti-VEGF agents, such as ranibizumab [4] and aflibercept [5], have been widely and effectively used worldwide in the clinical treatment of nAMD via targeting choroidal neovascularization. Mast cells secrete VEGF, a potent inducer of neof ormation of blood vessels and named vascular permeability factor (VPF), responsible for increased vascular permeability. Nevertheless, about one-third of patients do not get effects from anti-VEGF therapy owing to macular fibrosis or atrophy [9].

The fact that inflammation appears early in AMD pathology may explain why anti-inflammatory agents are beneficial as preventive or adjunctive therapies in combination with anti-VEGF therapy. Mast cells stimulate inflammation through the release of TNF- α , which in turn, recruits inflammatory cells including macrophages and neutrophils. Moreover, mast cells promote dendritic cell migration to lymph nodes through TNF- α , histamine, and IL-6 and promote anti-tumor T-cell phenotypes through histamine. In this context, although anti-VEGF factor therapy is the first line of defense against neovascular AMD, anti-inflammatory agents such as corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), immunosuppressive agents (e.g., methotrexate and rapamycin), and biologics (e.g., infliximab, daclizumab, and complement inhibitors) may provide an adjunct or alternative mechanism to suppress the inflammatory processes in AMD.

More specifically, stabilization of mast cell degranulation is another therapeutic strategy for targeting mast cells and preventing or abrogating their activation. Disodium cromoglycate, which inhibits mast cell degranulation, lowered the rate of serous retinal detachment from 80 to 16% when it was administered before the degranulation-activating compound. Tranilast, an anti-allergic drug that inhibits the release of chemical mediators from mast cells, suppresses laser-induced choroidal neovascularization in the rat [23].

Concluding remarks

Recently, it has been established that mast cells play a crucial role in AMD. Choroidal mast cells release different mediators, including histamine, cytokines, and proteases. Proteases, including tryptase, MMPs, and granzyme B, disrupt extracellular matrix leading to the degradation of the choriocapillaris basement membrane, endothelial damage, and vascular dropout [12]. Moreover, choroidal mast cells are located near the choroidal vasculature, intervening in the modulation of angio-inflammatory processes [10]. Finally, mast cells through the secretion of TNF- α recruit neutrophils and macrophages, amplifying the inflammatory response. The number of mast cells may be reduced by the targeted induction of apoptosis or by blocking their recruitment, migration, and differentiation. Many pharmacological agents have been developed that modulate mast cell functions. They block mediator receptors on target cells, including H1 receptor antagonists, CysLT1 receptor antagonists, and PGD₂ receptor antagonists; inhibit mast cell mediator synthesis, including omalizumab, disodium cromoglycate, and imatinib; block mast cell activation or mediator release, including steroids and NSAIDs. In this context, the inhibition of mast cell activation and of the

release of inflammatory mediators may be considered a novel therapeutic strategy in treating AMD.

Author contributions DR and RD helped with writing—original draft, designed the study. Both authors have read and agreed to the published version of the manuscript.

Funding Open access funding provided by Università degli Studi di Bari Aldo Moro within the CRUI-CARE Agreement.

Declarations

Conflict of interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

References

1. Bhutto IA, McLeod DS, Jing T, Sunness JS, Seddon JM, Luty GA. Increased choroidal mast cells and their degranulation in age-related macular degeneration. *Br J Ophthalmol*. 2016;100:720–6.
2. Coleman HR, Chan CC, Ferris FL III, Chew EY. Age-related macular degeneration. *Lancet*. 2008;372:1835–45.
3. Crivellato E, Beltrami CA, Mallardi F, Ribatti D. Paul Ehrlich's doctoral thesis: a milestone in the study of mast cells. *Br J Haematol*. 2003;123:19–21.
4. Frampton JE. Ranibizumab: a review of its use in the treatment of neovascular age-related macular degeneration. *Drugs Aging*. 2013;30:331–58.
5. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AY, Soo Y, Anderesi M, Groetzsch G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. *Ophthalmology*. 2012;119:2537–48.
6. Irani A, Schechter N, Craig S, DeBlois G, Schwartz L. Two types of human mast cells that have distinct neutral protease compositions. *Proc Natl Acad Sci USA*. 1986;83:4464–8.
7. Kitamura Y, Ito A. Mast cell-committed progenitors. *Proc Natl Acad Sci USA*. 2005;102:11129–30.
8. Levene RZ. Mast cells and amines in normal ocular tissues. *Invest Ophthalmol*. 1962;1:531–43.
9. Little K, Ma JH, Yang N, Chen M, Xu H. Myofibroblasts in macular fibrosis secondary to neovascular age-related macular degeneration – the potential sources and molecular cues for their recruitment and activation. *Ebio Med*. 2018;38:283–91.

10. Malih S, Song YS, Sorenson CM, Sheibani N. Choroidal mast cells and pathophysiology of age-related macular degeneration. *Cells*. 2023;13:50.
11. May CA. Mast cell heterogeneity in the human uvea. *Histochem Cell Biol*. 1999;1999(112):381–6.
12. Mcharg S, Booth L, Perveen R, Riba Garcia I, Brace N, Bayatti N, Sergouniotis PI, Phillips AM, Day AJ, Black GCM, Clark SJ, Dowsey AW, Unwin RD, Bishop PN. Mast cell infiltration of the choroid and protease release are early events in age-related macular degeneration associated with genetic risk at both chromosomes 1q32 and 10q26. *Proc Natl Acad Sci USA*. 2022;119:e2118510119.
13. McMenamin PG. The distribution of immune cells in the uveal tract of the normal eye. *Eye*. 1997;1997(11):183–93.
14. McLeod DS, Grebe R, Bhutto I, Merges C, Baba T, Luty GA. Relationship between RPE and choriocapillaris in age-related macular degeneration. *Invest Ophthalmol Vis Sci*. 2009;50(50):4982–91.
15. McLeod DS, Bhutto I, Edwards MM, Gedam M, Baldeosingh R, Luttyet GA. Mast cell-derived tryptase in geographic atrophy. *Invest Ophthalmol Vis Sci*. 2017;58:5887–96.
16. Miller ST, Barney NP, Gamache DA, Spellman JM, Yanni JM. Secretory response of mast cells contained in monodispersed human choroidal preparations. *Int Arch Allergy Immunol*. 1997;114:139–43.
17. Mitchell P, Liew G, Gopinath B, Wong TY. Age-related macular degeneration. *Lancet*. 2018;392:1147–59.
18. Penfold P, Killingsworth M, Sarks S. An ultrastructural study of the role of leucocytes and fibroblasts in the breakdown of Bruch's membrane. *Aust J Ophthalmol*. 1984;12:23–31.
19. Ribatti D, Crivellato E. Mast cells, angiogenesis, and tumor growth. *Biochem Biopys Acta*. 2012;1822:2–8.
20. Ribatti D. The staining of mast cells: a historical overview. *Int Arch Allergy Immunol*. 2018;176:55–60.
21. Ribatti D, d'Amati A. Haematopoiesis and mast cell development. *Int J Mol Med*. 2023;24:10679.
22. Ribatti D. Mast cells at the interface between the external environment and the inner organism. *Front Med*. 2024;10:1332047.
23. Takehana Y, Kurokawa T, Kitamura T. Suppression of laser-induced choroidal neovascularization by oral tranilast in the rat. *Invest Ophthalmol Vis Sci*. 1999;40:459–66.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.